Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 8/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18151512 | 0.89 | ATM (0.42) | TNFATMMTOR | |
| SCHEMBL29795081 | 0.87 | TNF (0.40) | TNFCCNCCDK8ATMPIK3CA | |
| SCHEMBL18150897 | 0.87 | TNF (0.40) | TNFCCNCCDK8ATMPIK3CA | |
| SCHEMBL18150959 | 0.86 | TNF (0.38) | TNFCCNCCDK8ATMPIK3CA | |
| SCHEMBL18151156 | 0.84 | TNF (0.38) | TNFCCNCCDK8ATMP2RX7 | |
| SCHEMBL18150817 | 0.84 | TNF (0.38) | TNFCCNCCDK8ATMP2RX7 | |
| SCHEMBL18153251 | 0.83 | TNF (0.37) | TNFCCNCCDK8ATMPIK3CA | |
| SCHEMBL18150881 | 0.83 | TNF (0.37) | TNFCCNCCDK8ATMPIK3CA | |
| SCHEMBL18150804 | 0.83 | FTO (0.37) | TNFCCNCCDK8ATMPIK3CA | |
| SCHEMBL18151632 | 0.83 | PIK3CB (0.40) | TNFCCNCCDK8ATMP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | TNF 1/4885CCNC 1982/4885CDK8 913/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | TNF 1/4885CCNC 1982/4885CDK8 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.